ALRinactive

ALERE INC.

Healthcare·Immunology·Pre-clinical
Immunology

ALERE INC. (ALR): 4 pipeline candidates · ~45 mo cash runway. Updated within the last hour.

7.3/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

44.6 months

Financial Health10.0

0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ALERE INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$491.7M

Quarterly Burn

$51.1M

Runway

44.6 mo

Revenue

$554.7M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2030
Today~49 mo out
Catalyst within runway

Pipeline (4 candidates)

·CEO: Gregg J. Powers

Frequently asked questions

How many drug candidates are in ALERE INC.'s pipeline?

ALERE INC. (ALR) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ALERE INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ALERE INC. has approximately 44.6 months of cash runway.

Who is the CEO of ALERE INC.?

Gregg J. Powers is the chief executive officer of ALERE INC. (ALR).

Get the full picture on ALERE INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.